Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30 results about "Glutamate kinase" patented technology

Recombinant corynebacterium crenatum for over expression of N-acetylglutamate kinase and application thereof

The invention relates to a recombinant corynebacterium crenatum to enhance the expression of N-acetyl glutamic acid kinase and the application thereof, which belongs to the technical field of gene engineering. The classification and nomenclature of the recombinant corynebacterium crenatum to enhance the expression of N-acetyl glutamic acid kinase is corynebacterium crenatum SYPA / pJC1-tac-argB with an access number of CCTCC NO: M 208133; The application is as follows: using a key enzyme N-acetyl glutamic acid kinase from corynebacterium crenatum pathway arginine to construct a corynebacterium crenatum expression vector pJC1-tac-argB; introducing the corynebacterium crenatum expression vector pJC1-tac-argB into corynebacterium crenatum SYPA by electrotransformation to obtain the recombinant corynebacterium crenatum SYPA / pJC1-tac-argB; and excessively expressing N-acetyl glutamic acid kinase, which greatly enhances the utilization rate of a precursor glutamic acid and allows the metabolic flow to flow to the arginine synthesis pathway, weakens the synthesis of proline, achieves the purpose of improving the output of arginine and the output of arginine is increased by 23.4 percent than C. crenatum SYPA.
Owner:JIANGNAN UNIV

Metabolic transformation method for efficiently improving production capacity of corynebacterium crenatum SYPA5-5 L-arginine

InactiveCN104059863ABacteriaMutant preparationTranscriptional analysisBacterial strain
The invention provides a metabolic transformation strategy for efficiently improving production capacity of corynebacterium crenatum SYPA5-5 L-arginine, and belongs to the biological technical field. Histidine at a site 268 in N-acetyl glutamatekinase, NAGK, argB of SYPA-5 is mutated into asparaginate, so that feedback inhibition effect of the L-arginine on NAGK can be effectively relived; a mutation site is precisely introduced to a corresponding position of SYPA5-5 genome, so that yield of the obtained feedback inhibition-preventing bacterial strain (H-7)L-arginine is lowered, and metabolic intermediate (L-ornithine and L-citrulline) is largely accumulated. Transcriptional analysis is carried out on an arg gene cluster of h-7 to find that arg GH transcriptional level is lowered. Arg GH reinforced expression is carried out in H-7, and production capacity of the obtained recombinant bacterial strain H-7-GH, L-arginine is improved by 99.0% in comparison with SYPA5-5. Preliminary optimization is carried out on a fermentation culture medium of H-7-GH, so that yield of the L-arginine is 45.1g / L, which is improved by 49.8% in comparison with that before optimization, and improved by 1.13 times in comparison with SYPA5-5. Feedback inhibition of the L-arginine on NAGK is relieved, and metabolic transformation strategy of the arg GH gene is expressed in a strengthened manner at the same time, so that production capacity of the L-arginine of the SYPA 5-5 is effectively improved.
Owner:JIANGNAN UNIV

Method for producing trans-4-hydroxyproline from glucose in fermentation manner

The invention discloses a method for producing trans-4-hydroxyproline from glucose in a fermentation manner by virtue of recombinant Escherichia coli without adding exogenous L-proline. A recombinant plasmid carried by the recombinant Escherichia coli has a mutant gene proBA2 and hyp (4-hydroxyproline), wherein proBA2 is mutated on a glutamyl kinase encoding gene proB, and the inhibition effect of L-proline on glutamyl kinase encoded by the mutated gene is remarkably reduced. proBA2 and hyp are co-expressed, and trans-4-hydroxyproline can be produced directly from glucose in the fermentation manner without adding exogenous L-proline. The recombinant plasmid is obtained by recombining proBA2 and hyp onto the same expression plasmid or by co-transforming recombinant plasmids which contain the two genes respectively and have different resistances. The invention further discloses the application of the Escherichia coli to the production of hydroxyproline.
Owner:JIANGNAN UNIV

N-acetylgutamate kinase mutant with heat stability improved remarkably

The invention discloses an N-acetylgutamate kinase mutant with heat stability improved remarkably and belongs to the field of bioengineering .The gene of N-acetylgutamate kinase from Corynebacterium crenatum SYPA5-5 is subjected to site-specific mutagenesis, so that lysine K at the site 234 of the encoded amino acid sequence is mutated into threonine T .the half-life period of the N-acetylgutamate kinase mutant at 37 DEG C is prolonged to be 112 h from 36 h of a wild type N-acetylgutamate kinase mutant, which is 3.11 times of the length before mutation .The N-acetylgutamate kinase mutant can better meet the production requirement of arginine, and lays a foundation for efficient synthesis of L-arginine.
Owner:JIANGNAN UNIV

Corynebacterium glutamicum for high yield of L-proline and method for high yield of L-proline

The invention provides corynebacterium glutamicum for producing L-proline and a method for producing the L-proline by using the strain. According to the corynebacterium glutamicum for producing the L-proline, proline dehydrogenase / pyrrole-5-carboxylate dehydrogenase PutA is inactivated, activity of glutamate kinase ProB, glutamic acid-5-semialdehyde dehydrogenase ProA, pyrrole-5-carboxylate dehydrogenase ProC, pyruvate carboxylase Pyc, glyceraldehyde-3-phosphate dehydrogenase GapN, L-proline efflux protein ThrE or SerE is enhanced, and activity of L-proline is enhanced. The L-glutamic acid efflux protein MscCG is inactivated, the L-proline yield, the conversion rate and the production intensity of the obtained strain are remarkably improved compared with those of an original strain, and the production cost of the L-proline can be reduced.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Ammonia (ammonia ion) determination method, ammonia (ammonia ion) diagnosis/determination kit

The invention relates to an ammonia (ammonia ion) content determination method by using an enzyme colorimetric method and an enzyme coupled reaction method, a reagent composition and components. The technical principle of the determination method is that a series of catalytic reactions can be carried out according to ammonia kinases, glutamine kinases and glutamine synthetase. The invention also relates to an ammonia (ammonia ion) diagnosis / determination kit. The determination method of invention has the advantages of high sensitivity and small error. The determination method and the kit of the present invention can be widely used for clinical medicine / food examination.
Owner:SUZHOU ANJ BIOTECHNOLOGY CO LTD

High-yield strain and construction method of cyclic lipopeptide antibiotics hemastatin

The invention discloses a high-producing strain for the cyclic lipopeptide antibiotic--himastatin and a construction method thereof. The high-producing strain for himastatin is constructed by inactivating the hmtA gene or hmtB gene of S. himastatinicus sp.Nov, so the high-producing mutant strain S. himastatinicus sp.Nov for himastatin is obtained, wherein the nucleotide sequence of the hmtA gene is as shown in SEQ ID No. 1 and the nucleotide sequence of the hmtB gene is as shown in SEQ ID No. 3. According to the invention, the hmtA-inactivated mutant strain S. himastatinicus sp.Nov Ju2014 and the hmtB-inactivated mutant strain S. himastatinicus sp.Nov Ju2015 are respectively obtained by inactivating the Mer-family transcriptional regulation gene hmtA and the acetyl glutamic acid kinase gene hmtB at the upper stream of the biosynthesis gene cluster of the cyclic lipopeptide antibiotic--himastatin of S. himastatinicus sp.Nov. The himastatin output of the mutant strain S. himastatinicus sp.Nov Ju2014 and the mutant strain S. himastatinicus sp.Nov Ju2015 is more than 10 times that of a wild strain S. himastatinicus sp.Nov. Thus, successful construction of the two high-producing mutant strains for the cyclic lipopeptide antibiotic--himastatin enables acceleration of the industrialization process of himastatin to be possible and hopeful.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY - CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products